

## Leflunomide (Arava®)

Leflunomide (Arava) is an isoxazole immunomodulatory agent that inhibits dihydroorotate dehydrogenase (a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity and anti-inflammatory effects.

### Resources from Manufacturer

[Full Prescribing Information](#)

### Indications and Dosing in Rheumatology

#### Leflunomide is indicated for:

- Adults with active rheumatoid arthritis

#### Dosing:

- Optional loading dosing: 100 mg orally daily for 3 days
  - For patients at low risk for leflunomide-associated hepatotoxicity or myelosuppression
- Maintenance dosing: 20 mg orally daily
  - Maximum recommended daily dosage is 20 mg once daily. If 20 mg is not tolerated, may decrease dosage to 10 mg once daily.

### Contraindications

- Pregnancy
- Severe hepatic impairment
- Known hypersensitivity
- Current teriflunomide treatment

### Warnings and Precautions

- Embryo-fetal toxicity—Leflunomide may cause fetal harm when administered to pregnant women, including teratogenicity and embryo-lethality. Exclude pregnancy prior to initiating leflunomide therapy and advise use of effective contraceptives in females of reproductive potential. Stop leflunomide and use accelerated drug elimination procedure if the patient becomes pregnant.
- Hepatotoxicity—Severe liver injury and fatal liver failure have been reported. Avoid use in patients with pre-existing liver disease or those with ALT > 2x ULN before treatment. Monitor LFTs monthly after start then every 6-8 weeks during treatment, with interruption in therapy recommended if ALT > 3x ULN.
- Serious Infections—Do not start leflunomide in patients with a severe active infection, immunodeficiency, or bone marrow dysplasia. Pancytopenia, agranulocytosis, thrombocytopenia, and opportunistic infections have been reported, however most frequently in patients on concomitant methotrexate, immunosuppressive agents, or history of hematologic abnormalities.
- Stevens-Johnson syndrome—SJS, toxic epidermal necrolysis, and drug reactions with eosinophilia and systemic symptoms (DRESS) have been reported. If occurs, discontinue leflunomide and use accelerated drug elimination procedure.
- Peripheral neuropathy—If patient develops symptoms consistent with peripheral neuropathy, evaluate further and consider discontinuing leflunomide.

## Warnings and Precautions *continued*

- Interstitial lung disease—May be fatal. New onset or worsening symptoms may necessitate discontinuation of leflunomide and consider accelerated drug elimination procedure.
- Increase blood pressure—Monitor and treat.

## Adverse Reactions

### Common (≥ 10%):

- Diarrhea
- Respiratory infection
- Nausea, dyspepsia
- Headache
- Rash
- Abnormal liver enzymes

## Medication Strength and Preparations

- 10 mg and 20 mg tablets

## Medication Administration and Monitoring

- Take 1 tablet by mouth once daily.
- Food does not have a significant impact on absorption or serum concentration.
- Store at room temperature and protect from light.

### Accelerated drug elimination procedure:

- After leflunomide discontinuation, the active metabolite (teriflunomide) is slowly eliminated from the plasma and may take up to 2 years to reach undetectable plasma concentrations. Accelerated drug elimination procedure should be considered for rapid reduction of drug levels in patients who have experienced a severe adverse reaction, has become pregnant, or of childbearing potential.
- Elimination procedure:
  - Administer cholestyramine 8 grams orally 3 times daily for 11 days.
  - Alternatively, administer 50 grams of activated charcoal powder (made into suspension) orally every 12 hours for 11 days.
  - Verify plasma teriflunomide concentrations <0.02 mg/L by 2 separate tests at least 14 days apart. Repeat procedure if concentrations are >0.02 mg/L.
- The duration of accelerated drug elimination treatment may be modified based on the clinical status and tolerability of the elimination procedure.

### Updated June 2023—ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology (“ACR”) for informational purposes only, in furtherance of its educational mission. It is not a substitute for user’s independent medical discretion or decision making, nor a replacement for the manufacturer’s complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide (including without limitation, any adverse effects).

# ACR/ARP Medication Guide

AMERICAN COLLEGE  
of RHEUMATOLOGY  
*Empowering Rheumatology Professionals*

ASSOCIATION of  
RHEUMATOLOGY  
PROFESSIONALS  
*The Interprofessional Division of the  
American College of Rheumatology*